LPCN
Price
$12.03
Change
+$1.02 (+9.27%)
Updated
Jan 15, 11:47 AM (EDT)
Capitalization
61.07M
Intraday BUY SELL Signals
VNDA
Price
$7.58
Change
-$0.12 (-1.56%)
Updated
Jan 15, 12:20 PM (EDT)
Capitalization
455.64M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LPCN vs VNDA

Header iconLPCN vs VNDA Comparison
Open Charts LPCN vs VNDABanner chart's image
Lipocine
Price$12.03
Change+$1.02 (+9.27%)
Volume$3.45K
Capitalization61.07M
Vanda Pharmaceuticals
Price$7.58
Change-$0.12 (-1.56%)
Volume$2K
Capitalization455.64M
LPCN vs VNDA Comparison Chart in %
LPCN
Daily Signal:
Gain/Loss:
VNDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LPCN vs. VNDA commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LPCN is a Hold and VNDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (LPCN: $11.00 vs. VNDA: $7.70)
Brand notoriety: LPCN and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LPCN: 271% vs. VNDA: 45%
Market capitalization -- LPCN: $61.07M vs. VNDA: $455.64M
LPCN [@Biotechnology] is valued at $61.07M. VNDA’s [@Biotechnology] market capitalization is $455.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LPCN’s FA Score shows that 0 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • LPCN’s FA Score: 0 green, 5 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, VNDA is a better buy in the long-term than LPCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LPCN’s TA Score shows that 5 TA indicator(s) are bullish while VNDA’s TA Score has 3 bullish TA indicator(s).

  • LPCN’s TA Score: 5 bullish, 4 bearish.
  • VNDA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, LPCN is a better buy in the short-term than VNDA.

Price Growth

LPCN (@Biotechnology) experienced а +46.28% price change this week, while VNDA (@Biotechnology) price change was -9.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

VNDA is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VNDA($456M) has a higher market cap than LPCN($61.1M). LPCN YTD gains are higher at: 36.986 vs. VNDA (-12.698). LPCN has higher annual earnings (EBITDA): -6.25M vs. VNDA (-113.07M). VNDA has more cash in the bank: 294M vs. LPCN (15.1M). LPCN has less debt than VNDA: LPCN (1.48M) vs VNDA (10.9M). VNDA has higher revenues than LPCN: VNDA (212M) vs LPCN (4.32M).
LPCNVNDALPCN / VNDA
Capitalization61.1M456M13%
EBITDA-6.25M-113.07M6%
Gain YTD36.986-12.698-291%
P/E RatioN/A126.00-
Revenue4.32M212M2%
Total Cash15.1M294M5%
Total Debt1.48M10.9M14%
FUNDAMENTALS RATINGS
LPCN vs VNDA: Fundamental Ratings
LPCN
VNDA
OUTLOOK RATING
1..100
3322
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3438
P/E GROWTH RATING
1..100
973
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (56) in the Pharmaceuticals Other industry is somewhat better than the same rating for VNDA (91) in the Biotechnology industry. This means that LPCN’s stock grew somewhat faster than VNDA’s over the last 12 months.

LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as VNDA (100) in the Biotechnology industry. This means that LPCN’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's SMR Rating (95) in the Biotechnology industry is in the same range as LPCN (97) in the Pharmaceuticals Other industry. This means that VNDA’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as VNDA (38) in the Biotechnology industry. This means that LPCN’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for LPCN (97) in the Pharmaceuticals Other industry. This means that VNDA’s stock grew significantly faster than LPCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LPCNVNDA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 7 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
LPCN
Daily Signal:
Gain/Loss:
VNDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSFCX23.090.15
+0.65%
Federated Hermes MDT Small Cap Value C
MVIAX20.170.10
+0.50%
Praxis Value Index A
MXBUX8.77N/A
N/A
Empower S&P Mid Cap 400® Index L
REEIX17.72-0.01
-0.06%
RBC Emerging Markets Equity I
LIAGX18.12-0.03
-0.17%
Lord Abbett International Growth I

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
+5.06%
SPRY - LPCN
63%
Loosely correlated
+4.24%
HYFT - LPCN
43%
Loosely correlated
-12.30%
ZNTL - LPCN
36%
Loosely correlated
+0.86%
VNDA - LPCN
28%
Poorly correlated
+3.49%
GLSI - LPCN
27%
Poorly correlated
+0.93%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with IVF. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then IVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
+3.49%
IVF - VNDA
40%
Loosely correlated
+1.01%
VCYT - VNDA
36%
Loosely correlated
-1.39%
OLMA - VNDA
36%
Loosely correlated
+3.16%
RANI - VNDA
34%
Loosely correlated
-1.41%
APLS - VNDA
33%
Loosely correlated
-4.69%
More